All In Biotech

Drug Trial Radar · NCT06396039

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

A Phase 4, Multicenter, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Oral Ozanimod for Relapsing Multiple Sclerosis (RMS) in Chinese Participants

Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

May 15, 2024

Primary completion

Dec 29, 2028

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • BMS-986374Drug

    Specified dose on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized relapse rate (ARR) over 36 monthsTime frame: Up to 3 years

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0009

    Beijing, China

  • Local Institution - 0025

    Fuzhou, China

  • Local Institution - 0010

    Guiyang, China

  • Local Institution - 0013

    Hohhot, China

  • Local Institution - 0014

    Shanghai, China

  • Local Institution - 0021

    Shenyang, China

  • Local Institution - 0001

    Tianjin, China

  • Local Institution - 0020

    Xianyang, China

  • Local Institution - 0002

    Beijing, Beijing Municipality, China

  • Local Institution - 0012

    Guangzhou, Guangdong, China

  • Local Institution - 0022

    Guangzhou, Guangdong, China

  • Local Institution - 0008

    Shenzhen, Guangdong, China

  • Local Institution - 0004

    Shijiazhuang, Hebei, China

  • Local Institution - 0006

    Harbin, Heilongjiang, China

  • Local Institution - 0018

    Zhengzhou, Henan, China

  • Local Institution - 0007

    Wuhan, Hubei, China

  • Local Institution - 0003

    Nanchang, Jiangxi, China

  • Local Institution - 0005

    Changchun, Jilin, China

  • Local Institution - 0015

    Taiyuan, Shan1xi, China

  • Local Institution - 0023

    Ürümqi, Shan1xi, China

  • Local Institution - 0016

    Shanghai, Shanghai Municipality, China

  • Local Institution - 0011

    Chengdu, Sichuan, China

  • Local Institution - 0024

    Kunming, Yunnan, China

  • Local Institution - 0019

    Hangzhou, Zhejiang, China

  • Local Institution - 0017

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.